Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...
Zacks.com on MSN13h
PFE Secures EU Nod for Expanded Use of RSV Vaccine AbrysvoThe latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA ...
The vaccine targets the F glycoprotein of the RSV, which is essential for the virus’s ability to infect host cells. While Moderna’s pipeline expansion continues, InvestingPro data shows the ...
Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...
Moderna (MRNA) announced that the Australian Therapeutic Goods Administration has granted approval for mRESVIA, an mRNA respiratory syncytial ...
Is it time to average down on a Moderna holding or begin a new position? Let's look at the company's recent performance and some catalysts that could push the stock higher to see if it deserves a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback